MedTrace Logo

Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

NCT00310492 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2015-12-29

No results posted yet for this study

Summary

This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis

Conditions

Interventions

BIOLOGICAL

subcutaneous immunotherapy

Updosing by 16 injections to 100,000 SQ-U

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Hendrik Wolf, PhD · ALK-SCHERAX Arzneimittel GmbH

  • Alexander Kapp, MD, Prof. · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-05-31
Completion
2009-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310492 on ClinicalTrials.gov